Replying to:
PROVIN : Phase I study of a propranolol (Hemangiol®) and oral metronomic vinorelbine (Navelbine®) combination for children and teenagers with refractory/relapsing solid tumors
With 2 grants obtained from the PHRC-K national grants and "l’Etoile de Martin" and drugs provided by Pierre Fabre Oncology we are ready to start our latest pediatric metronomics trial that will combine oral propranolol and oral metronomic navelbine in children with refractory/relapsing solid tumours. The trial is called PROVIN and should start recruiting patients Q2 2016. Pierre Fabre has agreed to provide drugs for the trial. The trial will be opened in 10 pediatric oncology centres in (...)
